Roberto Iacovelli/oncoinfo.it
Jan 29, 2024, 17:46
Roberto Iacovelli: Different results from 2 phase 3 studies on adjuvant IO for mRCC… what’s the reason?
Roberto Iacovelli, Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome shared on X:
Quoting Roberto Iacovelli‘s post:
“Different results from 2 phase 3 studies (CM914 and KN564) on adjuvant IO for mRCC in similar but not equal populations at GU24. What’s the reason?
- Tx duration ( 6 vs 12 months)
- Population
- Therapy.”
Amol Akhade, Senior Consultant medical oncologist and hematooncologist at Reliance Hospitals, replied with:
“May be just by pure chance. We don’t know.
Duration difference of 6 months vs 12 months of adjuvant treatment should not be the major reason. We already know that from adjuvant trastuzumab studies in early breast cancer.
It is the 4 th option.
Luck by chance.”
Source: Roberto Iacovelli/X and Amol Akhade/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12